Objectives: Hyperhidrosis in pediatric patients has been understudied. Post hoc analyses of two phase 3 randomized, vehicle-controlled, 4-week trials (ATMOS-1
| INTRODUCTION

Hyperhidrosis is characterized by excess sweat production beyond
what is necessary to maintain thermal homeostasis. In primary hyperhidrosis, idiopathic sympathetic nerve hyperactivity triggers excess sweating, most commonly of the axillae, palms, soles, or craniofacial regions. 1 Hyperhidrosis occurs in children and adults, with~4.8% of the US population (~15.3 million people) affected. 1, 2 In an online survey of US teens,~17.1% experienced excessive sweating, with a mean onset age of 11 years. 3 The substantial negative impact of hyperhidrosis on quality of life has been well established [4] [5] [6] [7] and equated as comparable to, or greater than, the impact of psoriasis or eczema. 8 In children, the condition negatively affects psychological and social development and well-being, which may consequently trigger emotional and social distress. 9 Hyperhidrosis largely remains underrecognized as a treatable medical condition, particularly for pediatric patients. 6, 10 Only 51% of patients discussed their excess sweating with a health care professional, possibly due to patients' inability to recognize symptoms as a medical condition and/or dissatisfaction with available therapies. 1, 11 Though not pediatric-specific, these findings highlight the need for increased awareness and new treatments. 6 Glycopyrronium tosylate (GT; formerly DRM04) is a topical anticholinergic approved by the US Food and Drug Administration (June 2018) for primary axillary hyperhidrosis in patients 9 years and older (QBREXZA ™ [glycopyrronium] cloth, 2.4%, for topical use). GT is applied once-daily to the axillae using a premoistened towelette. GT-treated patients had decreased sweating severity and sweat production, with improvements in quality of life vs vehicle-treated patients in two randomized, double-blind vehicle-controlled, pivotal phase three studies for primary axillary hyperhidrosis (ATMOS-1, N = 344 [NCT02530281]
and ATMOS-2, N = 353 [NCT02530294]). 12 ATMOS-1 and ATMOS-2 were the first randomized, controlled phase three trials in primary axillary hyperhidrosis to enroll pediatric patients, offering a unique perspective into this underserved population. To better characterize treatment outcomes in pediatric patients, pooled efficacy and safety data for pediatric (≥ 9 to ≤ 16 years) vs older patients (> 16 years)
were evaluated in a post hoc analysis of ATMOS-1 and ATMOS-2.
| MATERIALS AND METHODS
| Study design
ATMOS-1 (US and Germany sites) and ATMOS-2 (US sites only)
assessed the efficacy and safety of GT vs vehicle when applied once-daily for 4 weeks (Figure 1) . A detailed description of trial methodology and approval by local institutional review boards have been reported. 12 Patients were assessed in clinics at Weeks 1, 2, 3, and 4 (end of treatment).
| Study patients
Detailed inclusion and exclusion criteria are fully reported in the primary publication. 12 Briefly, patients were male or nonpregnant females ≥ 9 years of age (≥ 18 years in Germany) with primary axillary hyperhidrosis for ≥ 6 months, gravimetrically measured sweat production ≥ 50 mg/5 min in each axilla, Axillary Sweating Daily Diary (ASDD)/ASDD-Children (ASDD-C) axillary sweating severity item (Item 2) ≥ 4 (11-point scale), 13, 14 and Hyperhidrosis Disease Severity Scale (HDSS) ≥ 3 (4-point scale).
| Efficacy and safety assessments
In ATMOS-1 and ATMOS-2, coprimary efficacy end points were ASDD/ASDD-C Item 2 (sweating severity) responder rate (≥ 4-point improvement from Baseline) and mean absolute change from Baseline in gravimetrically measured sweat production (average of left and right axillae) at Week 4. 12 Whereas the adult ASDD assesses severity (Item 2), impact (Item 3), and bothersomeness (Item 4) of axillary sweating, the children's version only assesses severity (Item 2) and was completed by patients ≥ 9 to < 16 years. Item 2 was specifically developed and rigorously validated in accordance with FDA patientreported outcome (PRO) guidance 15 to support efficacy assessments for regulatory approval. A 4-point improvement was identified as the threshold for meaningful clinical response. 14 Gravimetrically measured sweat production was assessed once a week over a 5-minute period under controlled conditions across study sites.
ATMOS-1 and ATMOS-2 also assessed two additional PRO measures, namely the HDSS and Dermatology Life Quality Index (DLQI; patients > 16 years) and children's version (CDLQI; patients ≤ 16 years). The HDSS, a validated hyperhidrosis-specific PRO measure for assessing sweating severity, is a self-reported questionnaire that employs a scale from 1 (never noticeable/never interferes with daily activities) to 4 (intolerable/always interferes with daily activities). 16 Though widely used, the HDSS lacks a child-specific version and
does not conform to current regulatory standards for PRO measures 
| Statistical analysis
Analysis subgroups were defined based on the DLQI and CDLQI, which have rigid age cutoffs for questionnaire administration (DLQI was administered to those > 16 years while CDLQI was administered to those ≤ 16 years). Therefore, the pediatric subgroup included patients ≥ 9 to ≤ 16 years and the older subgroup included patients > 16 years. Since ASDD/ASDD-C Item 2 was psychometrically evaluated and validated, the standard age cutoffs (ASDD-C:
< 6 years; ASDD: ≥ 16 years) for questionnaire administration could be and were modified to match the subgroup definitions established by the DLQI/CDLQI. All efficacy and safety assessments were made according to these subgroup definitions.
Efficacy analyses were conducted on the intent-to-treat population (all patients who were randomized and dispensed study drug 
Patient had five drug-related events that led to discontinuation: mild vision blurred (bilateral), severe mydriasis (bilateral), severe dry mouth, severe urinary retention, and severe anhidrosis. GT, topical glycopyrronium tosylate 3 | RESULTS
| Patient disposition, demographics, and baseline disease characteristics
Of 697 patients randomized, 44 (GT, n = 25; vehicle, n = 19) comprised the pediatric subgroup ( Figure 2 ). Completion rates were similar among subgroups and > 90%. Demographics and Baseline disease characteristics were generally well matched among treatment arms and between subgroups (Table 1) . Although the older subgroup had greater gravimetrically measured sweat production at Baseline, the standard deviations were large across all treatment groups.
| Efficacy
Efficacy results at Week 4 were consistent among subgroups and the overall pooled population. 12 ASDD/ASDD-C Item 2 responder rates were nearly identical among GT-treated patients in the pediatric and older subgroups (59.9% vs 60.2%, respectively), and substantially greater for GT-vs vehicle-treated patients regardless of subgroup ( Figure 3A ). Differences in responder rates between GT and vehicle were observed as early as Week 1 and were maintained through Week 4 in both subgroups ( Figure 3B ).
Median change in gravimetrically measured sweat production is presented here given the small pediatric sample size and skewness of the data (ie, large standard deviations) ( Table 2) . GT-treated patients in the older subgroup had greater median absolute change from Baseline vs the pediatric subgroup (−80.6 vs −64.2 mg/5 minutes, respectively), and GT showed greater change vs vehicle in both subgroups. Mean percent change from Baseline in sweat production was similar among GT-treated patients in pediatric and older subgroups (−60.1% vs −56.2%, respectively), and greater for GT-vs vehicle-treated patients ( Table 2 ). The proportion of patients with ≥ 50% reduction in sweat production at Week 4 was similar between GT-treated pediatric and older patients (79.9% vs 74.3%; Table 2 
| Safety
Pediatric and older subgroups had similar safety profiles (Table 3) .
Slightly fewer pediatric patients reported TEAEs vs the older subgroup (Table 3) . Of two serious TEAEs reported, both occurred in the GT arm of the older subgroup and only one led to Intent-to-treat population.
P-values not calculated as these comparisons were post hoc and not designed or powered to detect differences. TEAEs vs GT-treated older subgroup patients (Table 3) ; the most frequently reported events were dry mouth and mydriasis in both subgroups. Of eight pediatric patients reporting anticholinergic TEAEs, most experienced ≥ 1 TEAE; all events were considered related to study treatment (Table 4 ). Most TEAEs in pediatric patients were mild, transient (resolving within approximately 2 weeks regardless of whether study drug was temporarily withheld), reversible, and were managed by temporarily withholding study treatment; TEAEs did not recur upon re-challenge. One pediatric patient discontinued (5 anticholinergic TEAEs, 4 of which were severe). Study drug was stopped on day of onset, and the TEAEs resolved within a week.
A similar proportion of patients across subgroups and treatment arms experienced LSRs (Table 5) . Regardless of subgroup, the majority of GT-and vehicle-treated patients did not experience LSRs; of those that did, most were mild.
| DISCUSSION
This post hoc analysis is the first to report efficacy and safety data of topical, once-daily GT in pediatric patients with primary axillary hyperhidrosis. Though a limitation of the trial is the small sample size of the pediatric subgroup, the majority of the assessments showed consistent results between subgroups, and all assessments showed an advantage of GT treatment vs vehicle.
Although large variability was observed with sweat measurements, it is important to note that the episodic nature of sweating can complicate interpretation of gravimetrically measured sweat production. 18 Despite this, both groups showed substantially reduced sweat production, and a greater proportion of GT-vs GT towelette contains the following excipients: citric acid, dehydrated alcohol, purified water, and sodium citrate. 22 Identical excipients were included in the vehicle comparator of the ATMOS trials to account for any potential effect due to a compound other than active drug. Though a vehicle effect was observed in these trials, GT-treated patients had a significantly greater response than that observed with vehicle. 12, 19 Glycopyrronium tosylate was generally well tolerated, and TEAEs in pediatric patients were qualitatively similar to those seen in the older subgroup and consistent with those expected with anticholinergics. Unlike mydriasis events in the older subgroup, which were largely unilateral (22 of 27 events), the majority in the pediatric Despite therapeutic options for axillary hyperhidrosis, patients generally remain dissatisfied with treatment. 6, 25 GT was FDAapproved in June 2018 for patients ≥ 9 years with primary axillary hyperhidrosis, representing the first approved treatment to include pediatric patients. For adults, this represents a second approved therapy in addition to onabotulinum toxinA; 26 a microwave device for sweat gland ablation 27 has also been cleared for use in adults.
Oral anticholinergics are used off-label even though side effects remain a challenge. In a retrospective study of the oral anticholinergic glycopyrrolate in pediatric patients, the most highly cited reason for interrupting therapy was being bothered by side effects (62%). 28 Topical administration can reduce overall drug exposure and may mitigate adverse event risk. 29 Pharmacokinetic data show that maximum plasma concentration with topical GT once-daily for 5 days was low and comparable between children and adults (C max = 0.07 ± 0.06 ng/mL in children age 10-17 years and C max = 0.08 ± 0.04 ng/mL for adults). 22 C max values for topical GT were lower than values reported in the literature for oral anticholinergics, though the potential for some systemic exposure with topical
GT cannot be excluded. 30, 31 A recent publication summarized favorable results on hyperhidrosis severity and quality of life in adolescents/young adults with topical administration of the anticholinergic oxybutynin, though this was a small (N = 10), uncontrolled pilot study. 32 The unmet need for new therapies may be addressed with GT, which in this analysis mitigated disease severity while improving quality of life in pediatric patients, with a favorable safety profile. Additional trials that prospectively include pediatric patients with primary axillary hyperhidrosis are needed to confirm and expand the findings described here.
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